Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Preparing For A Future With Wyeth, Pfizer Posts Ho-Hum Q1 Results

This article was originally published in The Pink Sheet Daily

Executive Summary

Although down, numbers are in line with expectations of the company and Wall Street.

You may also be interested in...

Pfizer’s Business Units Enable It To Be Nimble Even as It Grows

Wyeth integration is on track, with closing expected end of Q3 or Q4; anti-trust review is in early stages, with concern primarily about animal health overlap.

Publicity May Have Compounded Chantix Psychiatric Reports, Pfizer Implies

Adverse event reports jumped in Q3/Q4 following erratic patient's murder, FDA MedWatch alert and resulting publicity, firm says.

Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment

ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts